These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. In brief: Zanubrutinib (Brukinsa) for CLL or SLL. Med Lett Drugs Ther; 2023 Feb; 65(1670):e33-e34. PubMed ID: 36877243 [No Abstract] [Full Text] [Related]
10. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312 [No Abstract] [Full Text] [Related]
11. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Thompson PA; Ferrajoli A; O'Brien S; Wierda WG; Keating MJ; Burger JA Br J Haematol; 2015 Jul; 170(1):125-8. PubMed ID: 25522014 [No Abstract] [Full Text] [Related]
12. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. Titus-Rains KS; Brown JN; Hammond JM J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377 [TBL] [Abstract][Full Text] [Related]
13. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545 [TBL] [Abstract][Full Text] [Related]
14. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562 [No Abstract] [Full Text] [Related]
15. Zanubrutinib in B-cell malignancies. Das M Lancet Oncol; 2019 Sep; 20(9):e470. PubMed ID: 31378456 [No Abstract] [Full Text] [Related]
16. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Rhodes JM; Mato AR Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166 [TBL] [Abstract][Full Text] [Related]
17. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429 [TBL] [Abstract][Full Text] [Related]
18. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101 [TBL] [Abstract][Full Text] [Related]
19. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Tran PN; O'Brien S Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951 [TBL] [Abstract][Full Text] [Related]
20. Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel. Mauro FR; Tedeschi A; Varettoni M; Zaja F; Barosi G; Zinzani PL Hematol Oncol; 2024 Mar; 42(2):e3255. PubMed ID: 38362952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]